Mr Phil Willis MP, Chairman of the House of Commons’ Science and Technology Select Committee, who unveiled the plaque said, “It is a huge privilege to officially open the new ‘Minerva’ research facility which offers emerging biotech companies state of the art facilities to bring excellent science to the market. This facility is a superb example of how government funding can stimulate knowledge transfer by sponsoring direct links between academia and industry and stimulating wealth creation in the regions.”
Minerva is the first of three BioDevelopment buildings, offering flexible laboratory and office accommodation, which are anticipated will stimulate and facilitate the knowledge transfer process from research to commercial exploitation on the campus. Dr David Hardman, CEO of BBT said, “This BioDevelopment building is the latest development in our Babraham Research Campus strategy to integrate world class science with innovative bioventures to exploit new technologies relating to human healthcare. This building enables companies to expand into new facilities on flexible terms, a unique proposition in the region. The campus has been home to over 40 of the region’s biotechnology companies since it opened in 1998 and BBT will start a new Bioincubator building in September. The continued success emphasises the role our knowledge-based campus can play in promoting biosciences for regional development.”
Cambridge Biotechnology Ltd, a drug-discovery research company developing novel therapeutics for the treatment of pain, inflammation and obesity, is one of the four companies residing in Minerva. Dr Peter Richardson, Managing Director of CBT said, "Moving to new facilities at Babraham represents a major new phase in the growth of CBT. The new laboratories will provide CBT's drug discovery teams with excellent working conditions and will ensure optimal efficiency and safety for all its research staff. A location on the Babraham Research Campus also benefits from the proximity of a host of innovative biotech companies and prestigious academic groups which provides an optimal environment for a company such as CBT to thrive."
Also in Minerva are NovaThera Ltd, a spin-out from Imperial College London that is pioneering applications of biomaterials and stem cell biology for regenerative medicine and tissue engineering, and Stem Cell Sciences plc, an international company with centres in the United Kingdom, Australia, Japan and the USA. Active in the stem cell research field since 1994, the company is principally focused on expertise to grow, differentiate, select and purify stem cells. Cyclacel, the Dundee-based biopharmaceutical company dedicated to the discovery, development and commercialisation of novel, mechanism-targeted drugs to treat human cancers, moved into Minerva from the Bioincubator facilities earlier this year.
Claire Cockcroft | alfa
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences